| . | Pretreatment . | Posttreatment . | Wilcoxon Signed-Rank Test . | ||||
|---|---|---|---|---|---|---|---|
| Measure . | M (SD) . | Mdn . | M (SD) . | Mdn . | Z . | P . | r (95% CI) . |
| Processes | |||||||
| CPAQ | 47.74 (18.35) | 46.00 | 54.11 (19.87) | 54.00 | 4.0* | < 0.001 | 0.39 (0.22 to 0.54) |
| FMI | 27.30 (7.29) | 26.00 | 31.02 (7.54) | 30.00 | 5.46* | < 0.001 | 0.52 (0.37 to 0.66) |
| AAQ-II | 23.13 (8.70) | 22.00 | 26.10 (9.82) | 24.00 | 3.86* | < 0.001 | 0.37 (0.20 to 0.53) |
| Somatic outcomes | |||||||
| PI | 5.73 (1.74) | 5.50 | 5.09 (1.79) | 5.00 | −4.2* | < 0.001 | −0.40 (-0.56 to -0.23) |
| PHQ-15 | 14.53 (4.77) | 14.00 | 13.13 (5.38) | 13.00 | −3.98* | < 0.001 | −0.38 (-0.54 to -0.21) |
| PCS-12 | 33.60 (7.58) | 33.12 | 35.38 (8.27) | 34.62 | 2.21 | 0.014 | 0.21 (0.03 to 0.39) |
| Psychological outcomes | |||||||
| MCS-12 | 30.74 (8.34) | 29.38 | 36.03 (9.70) | 34.99 | 5.52* | < 0.001 | 0.53 (0.38 to 0.66) |
| PHQ-9 | 15.44 (5.44) | 15.00 | 11.75 (5.63) | 11.00 | −6.43* | < 0.001 | −0.62 (-0.73 to -0.48) |
| GAD-7 | 10.55 (2.52) | 11.00 | 9.20 (2.59) | 9.00 | −4.94* | < 0.001 | −0.47 (-0.62 to -0.32) |
| . | Pretreatment . | Posttreatment . | Wilcoxon Signed-Rank Test . | ||||
|---|---|---|---|---|---|---|---|
| Measure . | M (SD) . | Mdn . | M (SD) . | Mdn . | Z . | P . | r (95% CI) . |
| Processes | |||||||
| CPAQ | 47.74 (18.35) | 46.00 | 54.11 (19.87) | 54.00 | 4.0* | < 0.001 | 0.39 (0.22 to 0.54) |
| FMI | 27.30 (7.29) | 26.00 | 31.02 (7.54) | 30.00 | 5.46* | < 0.001 | 0.52 (0.37 to 0.66) |
| AAQ-II | 23.13 (8.70) | 22.00 | 26.10 (9.82) | 24.00 | 3.86* | < 0.001 | 0.37 (0.20 to 0.53) |
| Somatic outcomes | |||||||
| PI | 5.73 (1.74) | 5.50 | 5.09 (1.79) | 5.00 | −4.2* | < 0.001 | −0.40 (-0.56 to -0.23) |
| PHQ-15 | 14.53 (4.77) | 14.00 | 13.13 (5.38) | 13.00 | −3.98* | < 0.001 | −0.38 (-0.54 to -0.21) |
| PCS-12 | 33.60 (7.58) | 33.12 | 35.38 (8.27) | 34.62 | 2.21 | 0.014 | 0.21 (0.03 to 0.39) |
| Psychological outcomes | |||||||
| MCS-12 | 30.74 (8.34) | 29.38 | 36.03 (9.70) | 34.99 | 5.52* | < 0.001 | 0.53 (0.38 to 0.66) |
| PHQ-9 | 15.44 (5.44) | 15.00 | 11.75 (5.63) | 11.00 | −6.43* | < 0.001 | −0.62 (-0.73 to -0.48) |
| GAD-7 | 10.55 (2.52) | 11.00 | 9.20 (2.59) | 9.00 | −4.94* | < 0.001 | −0.47 (-0.62 to -0.32) |
AAQ-II = Acceptance and Action Questionnaire II; CPAQ = Chronic Pain Acceptance Questionnaire; FMI = Freiburg Mindfulness Inventory; GAD-7 = Generalized Anxiety Disorder, 7-item scale; M = mean; MCS-12 = Mental Component Summary of Short-Form 12; Mdn = median; PCS = Physical Component Summary of Short-Form 12; PHQ-9 = Patient Health Questionnaire, 9-item depression scale; PHQ-15 = Patient Health Questionnaire, 15-item somatization scale; PI = pain intensity.
Bonferroni corrected P < 0.001.
| . | Pretreatment . | Posttreatment . | Wilcoxon Signed-Rank Test . | ||||
|---|---|---|---|---|---|---|---|
| Measure . | M (SD) . | Mdn . | M (SD) . | Mdn . | Z . | P . | r (95% CI) . |
| Processes | |||||||
| CPAQ | 47.74 (18.35) | 46.00 | 54.11 (19.87) | 54.00 | 4.0* | < 0.001 | 0.39 (0.22 to 0.54) |
| FMI | 27.30 (7.29) | 26.00 | 31.02 (7.54) | 30.00 | 5.46* | < 0.001 | 0.52 (0.37 to 0.66) |
| AAQ-II | 23.13 (8.70) | 22.00 | 26.10 (9.82) | 24.00 | 3.86* | < 0.001 | 0.37 (0.20 to 0.53) |
| Somatic outcomes | |||||||
| PI | 5.73 (1.74) | 5.50 | 5.09 (1.79) | 5.00 | −4.2* | < 0.001 | −0.40 (-0.56 to -0.23) |
| PHQ-15 | 14.53 (4.77) | 14.00 | 13.13 (5.38) | 13.00 | −3.98* | < 0.001 | −0.38 (-0.54 to -0.21) |
| PCS-12 | 33.60 (7.58) | 33.12 | 35.38 (8.27) | 34.62 | 2.21 | 0.014 | 0.21 (0.03 to 0.39) |
| Psychological outcomes | |||||||
| MCS-12 | 30.74 (8.34) | 29.38 | 36.03 (9.70) | 34.99 | 5.52* | < 0.001 | 0.53 (0.38 to 0.66) |
| PHQ-9 | 15.44 (5.44) | 15.00 | 11.75 (5.63) | 11.00 | −6.43* | < 0.001 | −0.62 (-0.73 to -0.48) |
| GAD-7 | 10.55 (2.52) | 11.00 | 9.20 (2.59) | 9.00 | −4.94* | < 0.001 | −0.47 (-0.62 to -0.32) |
| . | Pretreatment . | Posttreatment . | Wilcoxon Signed-Rank Test . | ||||
|---|---|---|---|---|---|---|---|
| Measure . | M (SD) . | Mdn . | M (SD) . | Mdn . | Z . | P . | r (95% CI) . |
| Processes | |||||||
| CPAQ | 47.74 (18.35) | 46.00 | 54.11 (19.87) | 54.00 | 4.0* | < 0.001 | 0.39 (0.22 to 0.54) |
| FMI | 27.30 (7.29) | 26.00 | 31.02 (7.54) | 30.00 | 5.46* | < 0.001 | 0.52 (0.37 to 0.66) |
| AAQ-II | 23.13 (8.70) | 22.00 | 26.10 (9.82) | 24.00 | 3.86* | < 0.001 | 0.37 (0.20 to 0.53) |
| Somatic outcomes | |||||||
| PI | 5.73 (1.74) | 5.50 | 5.09 (1.79) | 5.00 | −4.2* | < 0.001 | −0.40 (-0.56 to -0.23) |
| PHQ-15 | 14.53 (4.77) | 14.00 | 13.13 (5.38) | 13.00 | −3.98* | < 0.001 | −0.38 (-0.54 to -0.21) |
| PCS-12 | 33.60 (7.58) | 33.12 | 35.38 (8.27) | 34.62 | 2.21 | 0.014 | 0.21 (0.03 to 0.39) |
| Psychological outcomes | |||||||
| MCS-12 | 30.74 (8.34) | 29.38 | 36.03 (9.70) | 34.99 | 5.52* | < 0.001 | 0.53 (0.38 to 0.66) |
| PHQ-9 | 15.44 (5.44) | 15.00 | 11.75 (5.63) | 11.00 | −6.43* | < 0.001 | −0.62 (-0.73 to -0.48) |
| GAD-7 | 10.55 (2.52) | 11.00 | 9.20 (2.59) | 9.00 | −4.94* | < 0.001 | −0.47 (-0.62 to -0.32) |
AAQ-II = Acceptance and Action Questionnaire II; CPAQ = Chronic Pain Acceptance Questionnaire; FMI = Freiburg Mindfulness Inventory; GAD-7 = Generalized Anxiety Disorder, 7-item scale; M = mean; MCS-12 = Mental Component Summary of Short-Form 12; Mdn = median; PCS = Physical Component Summary of Short-Form 12; PHQ-9 = Patient Health Questionnaire, 9-item depression scale; PHQ-15 = Patient Health Questionnaire, 15-item somatization scale; PI = pain intensity.
Bonferroni corrected P < 0.001.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
